|
Absenteeisma
|
|---|
|
Week 16
| |
PBO (N = 104)
|
IXE Q4W (N = 114)
|
IXE Q2W (N = 98)
|
|
Nx
|
57
|
47
|
46
|
|
LSM (SE)
|
− 1.2 (2.8)
|
− 4.7 (2.9)
|
− 6.9 (3.1)
|
|
Mean (SD)
|
− 2.6 (28.6)
|
− 7.5 (20.2)
|
− 8.0 (24.2)
|
|
Week 52
| |
PBO/IXE (N = 93)
|
IXE Q4W/IXE Q4W (N = 98)
|
IXE Q2W/IXE Q2W (N = 90)
|
|
Nx
|
49
|
45
|
46
|
|
Mean (SD)
|
− 6.7 (26.2)
|
− 11.8 (25.9)
|
− 10.0 (27.1)
|
|
Presenteeisma
|
|---|
|
Week 16
| |
PBO (N = 104)
|
IXE Q4W (N = 114)
|
IXE Q2W (N = 98)
|
|
Nx
|
54
|
44
|
43
|
|
LSM (SE)
|
− 8.9 (3.6)
|
− 19.5 (3.9)*
|
− 22.2 (4.1)*
|
|
Mean (SD)
|
− 8.8 (32.7)
|
− 21.3 (23.6)
|
− 25.6 (26.5)
|
|
Week 52
| |
PBO/IXE (N = 93)
|
IXE Q4W/IXE Q4W (N = 98)
|
IXE Q2W/IXE Q2W (N = 90)
|
|
Nx
|
47
|
42
|
43
|
|
Mean (SD)
|
− 24.0 (33.3)
|
− 22.4 (25.6)
|
− 27.2 (27.0)
|
|
Overall work impairmenta
|
|---|
|
Week 16
| |
PBO (N = 104)
|
IXEQ4W (N = 114)
|
IXEQ2W (N = 98)
|
|
Nx
|
54
|
44
|
43
|
|
LSM (SE)
|
− 9.8 (3.7)
|
− 21.0 (4.0)*
|
− 23.5 (4.2)*
|
|
Mean (SD)
|
− 9.8 (32.8)
|
− 23.0 (24.2)
|
− 26.3 (26.8)
|
|
Week 52
| |
PBO/IXE (N = 93)
|
IXE Q4W/IXE Q4W (N = 98)
|
IXE Q2W/IXE Q2W (N = 90)
|
|
Nx
|
47
|
42
|
43
|
|
Mean (SD)
|
− 24.5 (33.1)
|
− 24.1 (26.3)
|
− 26.7 (27.6)
|
|
Activity impairment
|
|---|
|
Week 16
| |
PBO (N = 104)
|
IXE Q4W (N = 114)
|
IXE Q2W (N = 98)
|
|
Nx
|
99
|
112
|
96
|
|
LSM (SE)
|
− 10.1 (2.6)
|
− 16.5 (2.4)
|
− 18.4 (2.7)*
|
|
Mean (SD)
|
− 8.3 (29.4)
|
− 20.2 (23.9)
|
− 21.2 (28.0)
|
|
Week 52
| |
PBO/IXE (N = 93)
|
IXEQ 4W/IXE Q4W (N = 98)
|
IXE Q2W/IXE Q2W (N = 90)
|
|
Nx
|
89
|
98
|
90
|
|
Mean (SD)
|
− 21.7 (28.4)
|
− 24.6 (24.8)
|
− 23.1 (26.2)
|
- LSM (SE) is from analysis of covariance (ANCOVA), with missing data imputed via modified baseline observation carried forward (mBOCF). Mean (SD) at week 16 is from observed data from the blind-dose extended treatment group. Mean (SD) at week 52 is presented with missing data imputed via mBOCF
- ANCOVA analysis of covariance, IXE Q4W 80 mg ixekizumab every 2 weeks, IXE Q4W 80 mg ixekizumab every 4 weeks, LSM least squares mean, mBOCF modified baseline observation carried forward, N number of patients in the treatment group, Nx number of patients in the analysis subgroup, PBO placebo
- p values were from ANCOVA (treatment vs. placebo) for week 16: *p < 0.05, ‡p < 0.01, †p < 0.001
- aAbsenteeism, presenteeism, and overall work impairment were measured in patients reporting part- or full-time work
- bAt week 16, patients receiving placebo (PBO) (COAST-V, COAST-W) or adalimumab (ADA) (COAST-V) were switched to ixekizumab (IXE) Q4W or Q2W. Data for IXE Q4W and IXE Q2W were combined for the PBO/IXE and ADA/IXE groups